Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
2023年5月8日 - 8:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: May 2023
Commission File Number: 001-38428
PolyPid Ltd.
(Translation of registrant’s name into
English)
18 Hasivim Street
Petach Tikva 495376, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
☒
Form 20-F ☐ Form 40-F
CONTENTS
On
May 5, 2023, PolyPid Ltd. (the “Company”) convened an Annual and Extraordinary General Meeting of Shareholders (the “Meeting”).
The
Meeting was called for the following purposes:
Proposal No. 1 |
To re-elect Kost Forer Gabbay & Kasierer, Certified Public Accountants, as the independent registered public accountants of the Company, and to authorize the board of directors of the Company to determine their compensation, until the next annual general meeting of the Company’s shareholders; |
Proposal No. 2 |
To re- elect eight members of the board of directors of the Company and approve their compensation; |
Proposal No. 3 |
To approve an option grant for the Company’s Chief Executive Officer, Ms. Dikla Czaczkes Akselbrad; |
Proposal No. 4 |
To approve repricing of options for the Company’s Chief Executive Officer, Ms. Dikla Czaczkes Akselbrad; |
Proposal No. 5 |
To approve repricing of options for the members
of the board of directors of the Company;
|
|
|
Proposal No. 6 |
To approve an extension of the Company’s
U.S. subplan under Company’s Amended and Restated 2012 Share Option Plan for U.S. tax purposes;
|
|
|
Proposal No. 7 |
To increase the Company’s authorized share
capital and to amend and restate the Company’s Articles of Association to reflect the same;
|
|
|
Proposal No. 8 |
To approve an amendment to the Articles of Association
of the Company to include an ‘Exclusive Forum’ section; and
|
|
|
|
To discuss the Company’s financial statements
for the fiscal year ended December 31, 2022.
|
At
the Meeting, a quorum was present and the shareholders of the Company approved Proposal Nos. 1 through 8 as originally proposed.
Amended and Restated
Articles of Association
Attached
hereto as Exhibit 99.1 is the Company’s Amended and Restated Articles of Association, which reflects the approval of Proposal Nos.
7 and 8 above.
The
Report on Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-257651)
and Form S-8 (File No. 333-239517 and File No. 333-271060), filed with the Securities and
Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or
reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
POLYPID LTD. |
|
|
|
Date: May 8, 2023 |
By: |
/s/ Dikla Czaczkes Akselbrad |
|
|
Name |
Dikla Czaczkes Akselbrad |
|
|
Title: |
Chief Executive Officer |
3
PolyPid (NASDAQ:PYPD)
過去 株価チャート
から 5 2024 まで 6 2024
PolyPid (NASDAQ:PYPD)
過去 株価チャート
から 6 2023 まで 6 2024